GSK stock has endured a torrid year-to-date - down 21% in a sector that is performing much better than the S&P. Click here to read my analysis of GSK stock.
Data from the ETNA-AF-Europe Registry provide insights on edoxaban in routine clinical practice in patient subpopulations including those who are frail, with heart failure or insulin-dependent diabetes1
New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations with atrial fibrillation (AF) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
GSK has increased its full year forecast up expecting 2022 sales to increase between 6 to 8 per cent and adjusted operating profit to climb between 13 to 15 per cent by the end of the year.